-
Drug Discovery & Therapeutics2 months agoWhole-genome sequencing reveals genetic predictors of rifabutin susceptibility in multidrug-resistant tuberculosis
Rifabutin, a lesser-known cousin of the frontline tuberculosis drug rifampicin, may hold new life as a treatment option for multidrug-resistant tuberculosis—but only for patients carrying specific...
-
Drug Discovery & Therapeutics2 months agoMetal nanoparticles show promise against drug-resistant superbugs
The global crisis of antimicrobial resistance has reached a critical inflection point, claiming nearly 1.27 million lives annually and threatening to undermine decades of medical progress....
-
Drug Discovery & Therapeutics2 months agoEco-friendly bismuth nanoparticle–chitosan composites show antimicrobial promise
Bismuth, a heavy metal long relegated to the margins of nanotechnology, is stepping into the antimicrobial spotlight thanks to a team of chemists in Pakistan who...
-
Drug Discovery & Therapeutics2 months agoMn2O3-Co3O4 Nanocomposite Enables Visible-Light Degradation and Electrochemical Detection of Trimethoprim
A simple, low-cost nanomaterial made from two abundant transition-metal oxides can both destroy one of the world’s most persistent antibiotic pollutants in sunlight and electrically detect...
-
Drug Discovery & Therapeutics2 months agoC. difficile Have Lasting Effects on the Infant Gut, Challenging Long-Held Assumption
A new study from CHOP challenges the assumption that infant C. difficile colonization is harmless, finding that it can reshape the developing gut and immune system...
-
Drug Discovery & Therapeutics2 months agoAbbVie’s cancer TCE etentamig hits the mark in myeloma
AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?
-
Drug Discovery & Therapeutics2 months agoBeyond the genome: Regeneron’s Abecasis on scaling drug discovery with genetic data
BIOCENTURY | DISCOVERY & TRANSLATIONBEYOND THE GENOME: REGENERON’S ABECASIS ON SCALING DRUG DISCOVERY WITH GENETIC DATAThe BioCentury Show: Target discovery outpaces data size at the Regeneron...
-
Drug Discovery & Therapeutics2 months agoStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing...
-
Drug Discovery & Therapeutics2 months agoAkeso, Summit cancer drug confirms lung cancer survival benefit
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
-
Drug Discovery & Therapeutics2 months agoBiocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule
The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen’s RenNano platform, in its research and development (R&D) activities focused on neuroscience...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
